5HT 2C receptor modulators

Details 5HT 2C receptor modulators 5HT 2C receptor modulators

2011-07-12

2011-07-12

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S215000, C514S217010, C540S543000, C540S586000, C540S593000

Reexamination Certificate

active

07977329

ABSTRACT:
The present invention relates to novel compounds of Formula (I):which act as 5HT2Creceptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.

REFERENCES:
patent: 3652543 (1972-03-01), Hoegerle
patent: 3716639 (1973-02-01), Hoegerle et al.
patent: 3795683 (1974-03-01), Brossi et al.
patent: 4108989 (1978-08-01), Holden
patent: 4111957 (1978-09-01), Holden et al.
patent: 4210749 (1980-07-01), Shetty
patent: 4233217 (1980-11-01), Shetty
patent: 4762845 (1988-08-01), Chu et al.
patent: 4988690 (1991-01-01), Effland et al.
patent: 5015639 (1991-05-01), Berger et al.
patent: 5178786 (1993-01-01), Jahnke et al.
patent: 5247080 (1993-09-01), Berger et al.
patent: 5275915 (1994-01-01), Kojima et al.
patent: 5387685 (1995-02-01), Powell et al.
patent: 5412119 (1995-05-01), Brussee et al.
patent: 5422355 (1995-06-01), White et al.
patent: 5691362 (1997-11-01), McCormick et al.
patent: 5750520 (1998-05-01), Danilewicz et al.
patent: 5856503 (1999-01-01), Aebi et al.
patent: 5861393 (1999-01-01), Danilewicz et al.
patent: 5925651 (1999-07-01), Hutchinson
patent: 5939415 (1999-08-01), Laufer et al.
patent: 5942535 (1999-08-01), Laufer et al.
patent: 5958943 (1999-09-01), Laufer et al.
patent: 6087346 (2000-07-01), Glennon et al.
patent: 6218385 (2001-04-01), Adam et al.
patent: 6900313 (2005-05-01), Wasserscheid et al.
patent: 6953787 (2005-10-01), Smith et al.
patent: 6972295 (2005-12-01), Hagmann et al.
patent: 1090797 (1980-12-01), None
patent: 2197789 (1995-08-01), None
patent: 500194 (1971-01-01), None
patent: 1944121 (1970-03-01), None
patent: 3315106 (1983-11-01), None
patent: 0007070 (1980-01-01), None
patent: 0080779 (1983-06-01), None
patent: 0096838 (1983-12-01), None
patent: 0161350 (1985-11-01), None
patent: 0174118 (1986-03-01), None
patent: 0285287 (1987-03-01), None
patent: 0285919 (1994-10-01), None
patent: 0987235 (2000-03-01), None
patent: 1074549 (2001-02-01), None
patent: 987235 (2003-12-01), None
patent: 1221324 (1971-02-01), None
patent: 1225053 (1971-03-01), None
patent: 1268243 (1972-03-01), None
patent: 1599705 (1981-10-01), None
patent: 5339263 (1993-12-01), None
patent: 06298746 (1994-10-01), None
patent: 08134048 (1996-05-01), None
patent: 09030960 (1997-02-01), None
patent: 90987258 (1997-03-01), None
patent: 7807819 (1978-07-01), None
patent: WO 8807858 (1988-10-01), None
patent: WO 9119698 (1991-12-01), None
patent: WO 9300094 (1993-01-01), None
patent: WO 9513274 (1995-05-01), None
patent: WO 9604271 (1996-02-01), None
patent: WO 9605194 (1996-02-01), None
patent: WO 9633993 (1996-10-01), None
patent: WO 97/24364 (1997-07-01), None
patent: WO 9806701 (1998-02-01), None
patent: WO 9840385 (1998-09-01), None
patent: WO 99/24411 (1999-05-01), None
patent: WO 0240471 (2002-05-01), None
patent: WO 0248124 (2002-06-01), None
patent: WO 02074746 (2002-09-01), None
patent: WO 03000663 (2003-01-01), None
patent: WO 03/027068 (2003-04-01), None
patent: WO 03/062392 (2003-07-01), None
patent: WO 03086306 (2003-10-01), None
patent: WO 2004037788 (2004-05-01), None
patent: WO2005/003096 (2005-01-01), None
patent: WO2005/019179 (2005-03-01), None
patent: WO2005/042490 (2005-05-01), None
patent: WO2005/042491 (2005-05-01), None
patent: WO 2006/013209 (2006-02-01), None
patent: WO 2006/043710 (2006-04-01), None
patent: WO2006/069363 (2006-06-01), None
patent: WO2006/071740 (2006-07-01), None
patent: WO 2007/120517 (2007-10-01), None
Chahal et al., IDdb Meeting Report May 17-18, 2000.
Chang et al., “Dopamine receptor binding properties of some 2, 3, 4, 5-tetrahydro-1H-3-benzazapine-7-ols with non-aromatic substituents in the 5-position”, Bioorg. Med. Chem. Lett. 2:399-402 (1992).
Deady et al., “Synthesis of some tetrahydro-2-and 3-benzazepines, and of hexahydro-3-benzazocine”, Journal of the Chemical Society, Perkins Transactions 1, 1973 pp. 782-783.
Di Chiara G., (2002) Behavioural Brain Research, 137: 75-114.
Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision, Washington, DC, American Psychiatric Association, 2000*.
Fuchs et al., “Total synthesis of (+/−)-lennoxamine and (+/−)-aphanorphine by intramolecular electrophilic aromatic substitution reactions of 2-amidoacroleins”, Organic Letters, 2001, pp. 3923-3925, 3(24) American Chemical Society.
Gallant et al., (1967) Current Therapy Research 9(11):579-81.
Gardent et al., “Sur quelques de l'amino-2-bromo-4 1H benzazepine-3 et de ses derives”, Bull Soc. Chim. France 2:600-605 (1968).
Gobert et al., (2000) Synapse 36: 205-221.
Gombar et al., “Pharmacokinetics of a series of 6-chloro-2, 3, 4, 5-tetrahydro-3-substituted-1H-3-berizazepines in rats”, Drug Metab. Disposition 16:367-372 (1988).
Greene et al., Protective Groups in Organic Syntheses, 2ndEd., Wiley and Sons, NY (1991)*.
Hassine-Coniac et al., “Preparation et properietes d'aldehydes dans la serie de la benzazapine-3”, Bull Soc. Chim. France 11:3985-3992 (1971).
Hazebroucq, “Acces a des I-H, tetrahydro-2, 3, 4, 5 benzazepines-3 one-1 et a des hexahydro imidazo isoquinoleines”, Ann. Chim. (1966) pp. 221-254.
Hester et al., (1968) J. Med. Chem. 11(1): 101.
Higgins et al., (2003) European Journal of Pharmacology, 480: 151.
Hitzig, P., (1994) Journal of Substance Abuse Treatment, 11(5): 489.
Im et al., (2003) Molecular Pharmacology, 64: 78-84.
Jenck et al., (1998) European Neuropsychopharmacology 8: 161 (Abstract).
Karasu et al., (2000) Practice Guideline for the Treatment of Patients with Major Depressive Disorder.
Ladd et al., “Synthesis and dopaminergic binding of 2-aryldopamine analogues: phenethylamines, 2-benzazepines, and 9-(Aminomethyl) fluorenes”, J. Med. Chem., vol. 29:1904-1912 (1986).
Lam RW, Levitt AJ (1999) (eds) Canadian Consensus Guidelines for the Treatment of Seasonal Affective Disorder, Clinical & Academic Publishing, Vancouver, BC, Canada.
Lennon et al., “Azabenzocycloheptenones Part XVIII. Amines and amino-ketones of the tetrahydro-3-benzazepine-1-one series”, J. Chem. Soc. Perkin Transacts. (1975) 7:622-626.
Linda D. Williams, Chemistry Demystified 123 (2003).
Macdonald et al., “Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfony1-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): A Potent and selective dopamine D.sub.3 Receptor Antagonist”, J. Med. Chem. 46:4952-4964 (2003) American Chemical Society.
Moline et al., (2001) Expert Consensus Guideline Series—Treatment of Depression in Women Mar. 2001, 112-113.
Müller et al., (2006) Trends in Pharmacological Sciences, 27(9): 455 (Abstract).
National Institute on Drug Abuse, Proceedings of the 41stAnnual Scientific Meeting (1979) pp. 356-401.
Orioto et al., “Benzolactams—I: Alkylation of 1,2,4,5-tetrahydro-3-methyl-3h-3-benzazepin-2-one with sodium hydride and alkyl halide”, Tetrahedron 36:1017-1021 (1980) Pergamon Press Ltd.
Orito et al. (Hokkaido Daigaku Kogakubu Kenkyu Hokoku (1979), (96), 41-44.
Orito et al., “Total synthesis of pseudo type of protopine alkaloids”, Heterocycles 14(1) 1980.
Pauvert et al., “Silver nitrate-promoted ring enlargement of 1-tribromomethyl-1,2-dihydro-and 1-tribromomethyl-1,2,3,4-tetrahydro-isoquinoline derivatives: application to the synthesis of the anti-anginal zalebradine”, Tetrahedron Letters 44:4203-4206 (2003) Pergamon Press Ltd.
Pawan et al., (1971) British Journal of Pharmacology, 41(2): 416P-417P (CAPLUS abstract).
Pecherer et al., “The Synthesis of Some 7- and 7,8-substituted 2,3,4,5-tetrahydro-1H-3benzazepines”, J. Heterocyclic Chemistry 8(5):779-783 (1971).
Perry et al., “Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men”, BMJ (1995) 310:560-564.
Piesla et al., (2001) Schizophrenia Research 49: 95.
Porras et al., (2002) Neuropsychopharmacology 26: 311-324.
Prom Science Integrity entry 156186, (

Affiliated with

Also associated with

Rating

5HT 2C receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5HT 2C receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5HT 2C receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2649454